Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Second Transurethral Resection of Bladder Tumor (re-TURBT), utDNA Testing (Urine Tumor DNA Detection).
- Who it may be relevant to
- Registry conditions: Bladder Cancer, Liquid Biopsy, Repeat Transurethral Resection of Bladder Tumor. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
The Guiding Value of Urinary Tumor DNA Testing in Repeat Transurethral Resection of Non-Muscle-Invasive Bladder Cancer: An Open-Label, Randomized Controlled, Multi-Center Clinical Study (Truce-LB01)
Overview
Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of newly diagnosed bladder cancers and is characterized by a high risk of recurrence and progression. Current guidelines recommend that patients with stage T1 NMIBC undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery to remove residual tumor, confirm staging, and obtain additional pathological information. However, the benefits of routine re-TURBT for all high-risk patients remain controversial, as many patients may not have residual disease, while the procedure carries surgical and anesthetic risks, physical and psychological burden, and additional healthcare costs. Urine tumor DNA (utDNA) refers to DNA fragments shed by tumor cells into urine. It can be detected using molecular assays with high sensitivity and specificity, offering a non-invasive method for bladder cancer diagnosis and surveillance. Previous studies have shown that positive utDNA results after initial TURBT may be associated with residual disease and higher recurrence risk. This multicenter, randomized controlled trial aims to evaluate whether utDNA testing can accurately identify NMIBC patients who are most likely to benefit from re-TURBT, thereby guiding the decision to perform the procedure. The goal is to optimize patient selection for re-TURBT, reduce unnecessary surgeries, and improve patient quality of life while maintaining oncologic safety.
Interventions
- Procedure Second Transurethral Resection of Bladder Tumor (re-TURBT)
Participants with NMIBC who have undergone initial TURBT will not receive utDNA testing and will undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery, in accordance with current clinical guidelines. - Diagnostic test utDNA Testing (Urine Tumor DNA Detection)
Participants with NMIBC who have undergone initial TURBT will receive urine tumor DNA (utDNA) testing. If utDNA is positive, the patient will undergo a second transurethral resection of bladder tumor (re-TURBT) within 2-6 weeks after the initial surgery. If utDNA is negative, re-TURBT will be omitted and patients will proceed to guideline-based adjuvant therapy or surveillance.
Primary outcome measures
- Recurrence-free survival (RFS) [Time frame: Up to 24 months from randomization]
Secondary outcome measures (3)
- Progression-free survival (PFS) [Time frame: Up to 24 months from randomization]
- Pathological outcomes of second transurethral resection (re-TURBT) [Time frame: Perioperative (day of repeat TURBT)]
- Patient-reported outcomes [Time frame: Up to 24 months from randomization.]
Eligibility criteria
Inclusion criteria
Participants must meet all of the following criteria to be eligible for the study:
- Male or female, aged 18 years or older.
- Histologically confirmed non-muscle-invasive bladder tumor, with no evidence of muscle-invasive bladder cancer or metastatic disease.
- Histologically confirmed urothelial carcinoma of the bladder or bladder tumor with urothelial carcinoma as the predominant component (>50%).
- At least one of the following conditions:
- Incomplete initial transurethral resection of bladder tumor (TURBT) or suspected incomplete resection.
- Absence of detrusor muscle in the initial TURBT pathological specimen (except for low-grade Ta stage tumors or carcinoma in situ \[CIS\]).
- T1 stage tumor.
- Willingness to provide a 50 mL urine sample between 2-6 weeks after the initial TURBT and prior to re-TURBT.
- Willingness to provide tumor tissue samples for pathological examination.
- Willingness to undergo genetic testing required for the trial.
Exclusion criteria
- Contraindications to transurethral resection of bladder tumor (TURBT).
- Concurrent malignancy of the upper urinary tract (ureter or renal pelvis).
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: No
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Open label
- Primary purpose
- Treatment
Study locations
China · 6 centers
- Nanchang Second People's Hospital — Nanchang
- Sun Yat-sen Memorial Hospital of Sun Yat-sen University — Guangzhou
- Xingtai People's Hospital — Xingtai
- The Second Affiliated Hospital of Kunming Medical University — Kunming
- The second hospital of Tianjin Medical University — Tianjin
- General Hospital of Tianjin Medical University — Tianjin
Identifiers
NCT: NCT07187635 · Truce-LB01